TOPLINE:
In a multicenter cohort study of 575 South Korean patients with BRCA1 or BRCA2 pathogenic variants, breast-conserving treatment demonstrated comparable oncologic outcomes to mastectomy over a median follow-up of 8.3 years. After propensity score matching, no significant differences between the two surgical approaches were found in terms of locoregional recurrence, distant recurrence, and overall survival.
METHODOLOGY:
- Breast-conserving treatment has been established as a viable alternative to mastectomy for patients with sporadic breast cancer, showing comparable prognoses.
- Current guidelines specify that patients with breast cancer with genetic predispositions, such as BRCA1 or BRCA2 pathogenic variants, may consider prophylactic bilateral mastectomy for risk reduction, though the suitability and safety of…